Adicet Bio Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
102
- Stock Symbol
-
ACET
- Investments
-
2
- Share Price
-
$2.93
- (As of Thursday Closing)
Adicet Bio General Information
Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Contact Information
Website
www.adicetbio.comCorporate Office
- 131 Dartmouth Street
- 3rd Floor
- Boston, MA 02116
- United States
Corporate Office
- 131 Dartmouth Street
- 3rd Floor
- Boston, MA 02116
- United States
Adicet Bio Stock Performance
As of 12-Nov-2026, Adicet Bio’s stock price is $2.93. Its current market cap is $27.4M with 9.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.93 | $2.99 | $2.84 - $11.20 | $27.4M | 9.4M | 230K | -$8.56 |
Adicet Bio Financials Summary
As of 30-Sep-2026, Adicet Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (38,495) | (6,730) | (104,596) | (79,879) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (90,713) | (116,144) | (121,332) | (146,511) |
| Net Income | (90,996) | (116,803) | (117,122) | (142,658) |
| Total Assets | 128,946 | 192,355 | 220,219 | 207,295 |
| Total Debt | 12,100 | 14,738 | 17,234 | 20,924 |
Adicet Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adicet Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Adicet Bio Comparisons
Industry
Financing
Details
Adicet Bio Competitors (28)
One of Adicet Bio’s 28 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| RAPT Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Genocea Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Adicet Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adicet Bio Patents
Adicet Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250025504-A1 | Treatment of b cell malignancies | Pending | 05-Dec-2021 | ||
| US-20250085287-A1 | Methods for detection of membrane bound glypican-3 | Pending | 19-Aug-2021 | ||
| US-20230009275-A1 | Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof | Pending | 03-Dec-2019 | ||
| WO-2021113558-A2 | Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof | Inactive | 03-Dec-2019 | ||
| WO-2021113558-A3 | Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof | Inactive | 03-Dec-2019 | C07K16/00 |
Adicet Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adicet Bio Acquisitions (2)
Adicet Bio’s most recent deal was a Merger/Acquisition with resTORbio for . The deal was made on 15-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| resTORbio | 15-Sep-2020 | Merger/Acquisition | Drug Discovery | ||
| Applied Immune Technologies | 27-Jan-2016 | Merger/Acquisition | Drug Discovery |
Adicet Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.19 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Adicet Bio FAQs
-
When was Adicet Bio founded?
Adicet Bio was founded in 2014.
-
Where is Adicet Bio headquartered?
Adicet Bio is headquartered in Boston, MA.
-
What is the size of Adicet Bio?
Adicet Bio has 102 total employees.
-
What industry is Adicet Bio in?
Adicet Bio’s primary industry is Biotechnology.
-
Is Adicet Bio a private or public company?
Adicet Bio is a Public company.
-
What is Adicet Bio’s stock symbol?
The ticker symbol for Adicet Bio is ACET.
-
What is the current stock price of Adicet Bio?
As of 12-Nov-2026 the stock price of Adicet Bio is $2.93.
-
What is the current market cap of Adicet Bio?
The current market capitalization of Adicet Bio is $27.4M.
-
Who are Adicet Bio’s competitors?
Fate Therapeutics, Kite Pharma, RAPT Therapeutics, Genocea Biosciences, and Adaptimmune Therapeutics are some of the 28 competitors of Adicet Bio.
-
What is Adicet Bio’s annual earnings per share (EPS)?
Adicet Bio’s EPS for 12 months was -$8.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
